Cerus Corp (CERS)

2.60
NASDAQ : Health Care
Prev Close 2.61
Day Low/High 2.54 / 2.64
52 Wk Low/High 1.93 / 6.59
Avg Volume 837.70K
Exchange NASDAQ
Shares Outstanding 109.14M
Market Cap 284.85M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cerus Corporation Reports Second Quarter 2017 Results

Cerus Corporation Reports Second Quarter 2017 Results

Cerus Corporation (NASDAQ: CERS) today announced financial results for the second quarter ended June 30, 2017.

Cerus Enters Into $40 Million Amended Growth Capital Agreement

Cerus Enters Into $40 Million Amended Growth Capital Agreement

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into a $40 million amended growth capital credit facility with Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and...

Cerus Announces Expanded Supply Agreement With French National Blood Service

Cerus Announces Expanded Supply Agreement With French National Blood Service

Cerus Corporation (NASDAQ: CERS) announced today the signing of two, new, expanded contracts with Établissement Français du Sang (EFS), the French National Blood Service, for the INTERCEPT Blood System.

Cerus Announces Collaboration With Central California Blood Center To Manufacture Pathogen-Reduced Cryoprecipitate

Cerus Announces Collaboration With Central California Blood Center To Manufacture Pathogen-Reduced Cryoprecipitate

Cerus Corporation (NASDAQ:CERS) announced today an agreement with the Central California Blood Center (CCBC) in which CCBC will manufacture pathogen-reduced cryoprecipitate ("cryo") for the company.

Cerus To Release Second Quarter 2017 Results On August 3, 2017

Cerus To Release Second Quarter 2017 Results On August 3, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its second quarter results will be released on Thursday, August 3, 2017, after the close of the stock market.

Commit To Purchase Cerus Corp. At $2, Earn 13.3% Annualized Using Options

Commit To Purchase Cerus Corp. At $2, Earn 13.3% Annualized Using Options

Investors eyeing a purchase of Cerus Corp. stock, but cautious about paying the going market price of $2.54/share, might benefit from considering selling puts among the alternative strategies at their disposal.

INTERCEPT Blood System Highlighted At The International Society Of Blood Transfusion (ISBT)

Cerus Corporation (NASDAQ:CERS) announced results of 16 abstracts presenting experiences with the INTERCEPT Blood System for platelets, plasma, and red blood cells during the 27 th Regional Congress of the International...

Cerus Provides Update On U.S. Platelet Additive Solution (PAS) Supply

Cerus Corporation (NASDAQ:CERS) announced today that the expected Fresenius Kabi platelet additive solution (PAS) shortage the company announced on May 23, 2017, could be less disruptive to blood center production of...

Biotech Movers: Cerus, Alexion, NantKwest

Biotech Movers: Cerus, Alexion, NantKwest

Cerus, Alexion Pharmaceuticals and NantKwest were among the biotech movers in premarket trading on Tuesday.

Cerus Provides U.S. Business Update

Cerus Corporation (NASDAQ: CERS) announced today that it received notification last week of a pending U.

First Patient Transfused In Cerus' Phase III RedeS Study Evaluating Safety And Efficacy Of The INTERCEPT Red Blood Cell System

Cerus Corporation (NASDAQ: CERS) announced today that the first patient has been transfused in Puerto Rico for the "INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus...

Cerus Announces Exercise Of Additional BARDA Contract Options Totaling $46.6 Million To Support INTERCEPT Red Blood Cell System Development

Cerus Corporation (NASDAQ: CERS) announced today that additional options totaling $46.

Notable Thursday Option Activity: CERS, BZH, CATM

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cerus Corp. , where a total volume of 3,279 contracts has been traded thus far today, a contract volume which is representative of approximately 327,900 underlying shares (given that every 1 contract represents 100 underlying shares).

Cerus Corporation Reports First Quarter 2017 Results

Cerus Corporation (NASDAQ: CERS) today announced financial results for the first quarter ended March 31, 2017.

Cerus To Release First Quarter 2017 Results On May 3, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results will be released on Wednesday, May 3, 2017, after the close of the stock market.

Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Cerus Corporation (NASDAQ:CERS) announced today that, on April 3, 2017, the compensation committee of the company's board of directors granted 21 new non-executive employees options to purchase an aggregate of...

First Week of CERS November 17th Options Trading

Investors in Cerus Corp. saw new options become available this week, for the November 17th expiration.

Cerus Corporation Reports Fourth Quarter And Year End 2016 Results

Cerus Corporation (NASDAQ:CERS) today announced financial results for the fourth quarter and year ended December 31, 2016.

Cerus To Present At The Cowen And Company 37th Annual Health Care Conference On March 8, 2017

Cerus Corporation (NASDAQ:CERS) announced today that William "Obi" Greenman, president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 37th Annual Health Care Conference at...

First Week of April 21st Options Trading For Cerus Corp.

Investors in Cerus Corp. saw new options become available this week, for the April 21st expiration.

Cerus To Release Fourth Quarter And Year End 2016 Results On March 7, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end results for 2016 will be released on Tuesday, March 7, 2017, after the close of the stock market.

Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Cerus Corporation (NASDAQ: CERS) announced today that, on January 3, 2017, the compensation committee of the company's board of directors granted fifteen new non-executive employees options to purchase an...

Relative Strength Alert For Cerus

Relative Strength Alert For Cerus

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of August 2017 Options Trading For Cerus (CERS)

First Week of August 2017 Options Trading For Cerus (CERS)

Investors in Cerus Corp. saw new options become available this week, for the August 2017 expiration.

Cerus Announces Exercise Of Additional BARDA Contract Options Totaling $10,825,555 For Activities Related To Its Planned Phase III Trial Of The INTERCEPT Red Blood Cell System

Cerus Announces Exercise Of Additional BARDA Contract Options Totaling $10,825,555 For Activities Related To Its Planned Phase III Trial Of The INTERCEPT Red Blood Cell System

Cerus Corporation (NASDAQ: CERS) announced today that additional options totaling $10,825,555 have been exercised under its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.

Cerus Provides An Update On The Timeline For The INTERCEPT Blood System For Red Blood Cells In Europe

Cerus Provides An Update On The Timeline For The INTERCEPT Blood System For Red Blood Cells In Europe

Cerus Corporation (NASDAQ:CERS) today provided an update on the timeline for the INTERCEPT Blood System for Red Blood Cells (RBCs) in Europe.

January 2017 Options Now Available For Cerus (CERS)

January 2017 Options Now Available For Cerus (CERS)

Investors in Cerus Corp. saw new options begin trading today, for the January 2017 expiration.

Cerus (CERS) Stock Surges on Q3 Results, Outlook

Cerus (CERS) Stock Surges on Q3 Results, Outlook

Cerus (CERS) reported a narrower-than-expected loss for the 2016 third quarter after yesterday's market close.

TheStreet Quant Rating: D- (Sell)